DESC0024006
Project Grant
Overview
Grant Description
Advanced portable low temperature plasma device for chronic wound disinfection and healing.
Awardee
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Durham,
North Carolina
United States
Geographic Scope
City-Wide
Related Opportunity
Zymeron Corporation was awarded
Project Grant DESC0024006
worth $200,000
from the Office of Science in July 2023 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 9 months and
was awarded through assistance program 81.049 Office of Science Financial Assistance Program.
The Project Grant was awarded through grant opportunity FY 2023 Phase I Release 2.
SBIR Details
Research Type
SBIR Phase I
Title
Advanced portable low temperature plasma device for chronic wound disinfection and healing
Abstract
Management of chronic wounds remains a clinical challenge, especially when the wounds are infected by either biofilms or antibiotic-resistant microbial pathogens. Low temperature plasma (LTP) technique has demonstrated its proof of concept as an effective, non-antibiotic approach for wound disinfection. So far, commercial medical LTP devices leverage the direct exposure of plasma plume to the wound tissue, which leads to an increased risk of irreversible tissue damage. Besides the safety concerns, high manufacturing expenses and low portability among many other disadvantages prevent the widespread clinical translations of the LTP technology. Zymeron proposes to develop ZymPlasTM, a convenient, portable, and highly effective low temperature plasma device for chronic wound disinfection and healing at the point of care. ZymPlas adopts innovative plasma chemistry, which allows effective wound disinfection without the direct exposure of wound tissue to plasma plume. Besides, the novel plasma generation system and the compact design allow cost-effective manufacturing and improved portability. In the Phase I period, Zymeron will design and construct a functioning ZymPlasTM prototype device and optimize the relevant plasma chemistry. Next, the wound disinfection efficacy of the prototype device will be evaluated in ex vivo wound biofilm models using both Gram-negative and Gram-positive strains. Finally, the prototype device will be tested in a well-established mouse chronic wound infection model to validate the efficacy of wound disinfection and healing. ZymPlas can address wound infection and biofilm issues and thus brings significant clinical benefits (e.g., decreasing the wound chronicity, restoring impaired healing, reducing regular care frequency, shortening wound closure time) and reduces the financial and medical burden. Moreover, ZymPlas is also ideal for other applications such as acute trauma treatment, burn treatment, and surgical disinfection. The portable device design, simple operation procedure, and disinfection efficiency could match numerous applications in wound healing and dermatology therapeutic areas.
Topic Code
C56-31a
Solicitation Number
DE-FOA-0002903
Status
(Complete)
Last Modified 8/14/23
Period of Performance
7/10/23
Start Date
4/9/24
End Date
Funding Split
$200.0K
Federal Obligation
$0.0
Non-Federal Obligation
$200.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
DESC0024006
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
892430 SC CHICAGO SERVICE CENTER
Funding Office
892401 SCIENCE
Awardee UEI
GAMMMRQ6QMN1
Awardee CAGE
7MVB7
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
Science, Energy Programs, Energy (089-0222) | General science and basic research | Grants, subsidies, and contributions (41.0) | $200,000 | 100% |
Modified: 8/14/23